SPN-820/821
Treatment-Resistant Depression (TRD)
Phase 2Active
Key Facts
Indication
Treatment-Resistant Depression (TRD)
Phase
Phase 2
Status
Active
Company
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a commercial-stage biopharma leader in CNS disorders, leveraging deep expertise in drug delivery and product development to build a diversified portfolio. The company has demonstrated consistent growth, earning recognition on lists like Forbes' America's Best Small Companies and Fortune's 100 Fastest Growing Companies. With a foundation of marketed products generating revenue, Supernus is strategically advancing mid- and late-stage pipeline candidates while maintaining a patient-centric culture and operational excellence.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| BHV-2100 (mGluR2/3 NAM) | Biohaven | Phase 1 |
| PCN-101 (R-ketamine) | atai Life Sciences | Phase 2 |
| VLS-01 (DMT) | atai Life Sciences | Phase 1 |
| Salvianolic Acid B | atai Life Sciences | Preclinical |
| GH001 | GH Research | Phase 2b |
| BMB-101 | Bright Minds Biosciences | Phase 2 |
| MW-101 | MindWalk Holdings | Phase 2 |
| NPH-101 | Neuphoria Therapeutics | Phase 1/2 |
| CYC-126 | Cyclerion Therapeutics | Phase 2 |